---

Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus

---

Original Article

Author Details : Ved Prakash*, Nidhi Goel, Sunil Verma

Volume : 7, Issue : 1, Year : 2020

Article Page : 26-33

https://doi.org/10.18231/j.ijpp.2020.006

Suggest article by email

Get Permission

---

Abstract

Introduction: Type 2 Diabetes Mellitus (T2DM) a serious, common chronic disease constituting a major public health issue worldwide. Yet no cure is available, education of populace is still the key to control this emerging epidemic. Novel drugs are being developed, some used as monotherapy or in-combination for effective glycaemic control.
Objective: Comparing the efficacy of Sitagliptin+Metformin versus Glimepiride+ Metformin on patients of T2DM.
Material and method: 30 weeks open labeled Randomized controlled study enrolling 80 patients of T2DM, divided into two groups with 40 patients in each. Group A given Metformin(500mg) with Sitagliptin(100mg) and group B given Metformin(500mg) with Glimepiride(1mg). HbA1c, FBG, PPBG were done at baseline, 15 and 30 weeks.
Results: Group A and Group B both leads to significant (<0>0.05) for FBG, PPBG at 15 and 30 weeks and HbA1c at 15weeks but was the difference was statistically significant (<0>
Conclusion: Sitagliptin with Metformin and Glimepiride with Metformin both causes efficient glycaemic control with no significant adverse reaction but the gylcaemic control of patients taking Sitagliptin with Metformin was slightly better as compared to patients taking Glimepiride with Metformin. Thus concluding Sitagliptin to be more efficacious than Glimepiride.

Keywords: Diabetes mellitus type II, Sitagliptin, Glimepiride, Metformin, HbA1c (glycosylated haemoglobin), Fasting blood glucose, Post-prandial blood glucose.

How to cite : Prakash V , Goel N, Verma S, Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus. Indian J Pharm Pharmacol 2020;7(1):26-33

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.